Abstract
Amyotrophic lateral sclerosis (ALS) is a severe progressive neurodegenerative disease. The cause is unknown, but genetic abnormalities have been identified in subjects with familial ALS and also in subjects with sporadic ALS. Environmental factors such as occupational exposure have been shown to be risk factors for the development of ALS. Patients differ in their clinical features and differ in the clinical course of disease. Immune abnormalities have been found in the central nervous system by pathological studies and also in the blood and CSF of subjects with ALS. Inflammation and immune abnormalities are also found in animals with a model of ALS due to mutations in the SOD1 gene. Previously it has been considered that immune abnormalities might contribute to the pathogenesis of disease. However more recently it has become apparent that an immune response can occur as a response to damage to the nervous system and this can be protective.
Keywords: Amyotrophic lateral sclerosis, biomarkers, immunity, inflammation, lymphocytes, protective immunity, T cells, neurodegenerative diseases, autoimmune diseases, dementia, heterogeneity, astrocytes, gene expression, nuclear medicine technology, PET imaging
Current Molecular Medicine
Title: The Role of Immune and Inflammatory Mechanisms in ALS
Volume: 11 Issue: 3
Author(s): P. A. McCombe and R. D. Henderson
Affiliation:
Keywords: Amyotrophic lateral sclerosis, biomarkers, immunity, inflammation, lymphocytes, protective immunity, T cells, neurodegenerative diseases, autoimmune diseases, dementia, heterogeneity, astrocytes, gene expression, nuclear medicine technology, PET imaging
Abstract: Amyotrophic lateral sclerosis (ALS) is a severe progressive neurodegenerative disease. The cause is unknown, but genetic abnormalities have been identified in subjects with familial ALS and also in subjects with sporadic ALS. Environmental factors such as occupational exposure have been shown to be risk factors for the development of ALS. Patients differ in their clinical features and differ in the clinical course of disease. Immune abnormalities have been found in the central nervous system by pathological studies and also in the blood and CSF of subjects with ALS. Inflammation and immune abnormalities are also found in animals with a model of ALS due to mutations in the SOD1 gene. Previously it has been considered that immune abnormalities might contribute to the pathogenesis of disease. However more recently it has become apparent that an immune response can occur as a response to damage to the nervous system and this can be protective.
Export Options
About this article
Cite this article as:
A. McCombe P. and D. Henderson R., The Role of Immune and Inflammatory Mechanisms in ALS, Current Molecular Medicine 2011; 11 (3) . https://dx.doi.org/10.2174/156652411795243450
DOI https://dx.doi.org/10.2174/156652411795243450 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Mn (III) Tetrakis (4-Benzoic Acid) Porphyrin Protects Against Neuronal and Glial Oxidative Stress and Death After Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Axonal Ionic Pathophysiology in Human Peripheral Neuropathy and Motor Neuron Disease
Current Neurovascular Research New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design Retracted: Zebrafish Caspase-3: Molecular Cloning, Characterization, Crystallization and Phylogenetic Analysis
Protein & Peptide Letters Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?
Current Pharmaceutical Design Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Exploring the Role of Stem Cell Therapy in Treating Neurodegenerative Diseases: Challenges and Current Perspectives
Current Stem Cell Research & Therapy AAV as a Gene Transfer Vector for the Treatment of Neurological Disorders: Novel Treatment Thoughts for ALS
Current Gene Therapy Effect of Antioxidants on Heavy Metals Induced Conformational Alteration of Cytochrome C and Myoglobin
Protein & Peptide Letters